key: cord-0873895-41i4jgki
authors: Sarkar, Soumya; Kannan, Sundara; Khanna, Puneet; Singh, Akhil Kant
title: Role of red blood cell distribution width, as a prognostic indicator in COVID‐19: A systematic review and meta‐analysis
date: 2021-06-06
journal: Rev Med Virol
DOI: 10.1002/rmv.2264
sha: 00092970eddd063aca001b5bb021be5557e47033
doc_id: 873895
cord_uid: 41i4jgki

The red blood cell distribution width (RDW), an indicator of anisocytosis has emerged as a potential tool for risk stratification of critically ill patients with sepsis. Prognostic predictors are of paramount interest for prompt intervention and optimal utilization of the healthcare system in this ongoing context of the Coronavirus Disease 2019 (COVID‐19) pandemic. The current systematic review and meta‐analysis aims to explore the utility of RDW in the prognosis of COVID‐19 patients. A comprehensive screening of electronic databases was performed up to 30th April 2021 after enrolling in PROSPERO (CRD42020206685). Observational studies or interventional studies, evaluating the impact of RDW in COVID‐19 outcomes (mortality and severity) are included in this meta‐analysis.Our search retrieved 25 studies, with a total of 18,392 and 3,446 COVID‐19 patients for mortality and disease severity outcomes. Deceased and critically ill patients had higher RDW levels on admission in comparison to survivors and non‐severe patients (SMD = 0.46; 95%CI 0.31–0.71; I (2) = 88% and SMD = 0.46; 95%CI 0.26–0.67; I (2) = 60%, respectively). In a sub‐group analysis of 2,980 patients, RDW > 14.5 has been associated with increased risk of mortality (OR = 2.73; 95%CI 1.96–3.82; I (2) = 56%). However, the evidences is of low quality. A higher level of RDW on admission in COVID‐19 patients is associated with increased morbidity and mortality. However, further studies regarding the cut‐off value of RDW are the need of the hour.

prognostic markers of COVID-19 severity are under evaluation since January 2020. 6 Red blood cell distribution width (RDW) is a commonly measured parameter in complete blood count (CBC) panels. It is usually reported as RDW standard deviation (RDW-SD) or RDW coefficient of variation (RDW-CV), which provides us with a measure of heterogeneity in the size of red blood cells (RBC), that is, anisocytosis. Traditionally, it is used as a parameter to differentiate various types of anaemia. 7 More recently, it has been established as a marker of inflammation. Various studies have established the predictive value of RDW in the severity of a spectrum of diseases like chronic kidney disease (CKD), 8 preeclampsia, 9 cardiovascular diseases 10 and cancers. 11 Incrementally increasing RDW values are associated with an increased risk of more severe disease and mortality. 12 Systemic inflammation has been associated with increased all-cause, cancer, cardiovascular and cerebrovascular mortality. 13 Recent studies have demonstrated that increasing RDW represents an increase in the risk of MI and death, independent of anaemia and cardiovascular risk factors. [14] [15] [16] Inflammation plays a major role in the pathogenesis and severity of COVID 19 disease, culminating in cytokine release syndrome (CRS) or cytokine storm in its most severe form. 17 Higher baseline CRP and IL-6 levels were associated with more incidence of ARDS and death. [18] [19] [20] RDW as a marker of pre-existing pro-inflammatory or chronic inflammatory state can be used as a predictor of COVID 19 disease progression. There have been several studies that have examined the relationship between admission RDW and its ability to predict mortality in COVID 19 disease. In this meta-analysis, we aim to systematically analyse the current evidence for the utility of elevated RDW on admission as a prognostic indicator of COVID 19 disease, as per the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA-P) guidelines.

We prospectively enrolled the protocol of this systematic review and meta-analyses in PROSPERO (ID: CRD42020206685), and there was no significant deviation from the published protocol. 

Prospective and retrospective comparative cohort studies, case series with a control group, cross-sectional studies, controlled clinical trials, case-control studies and randomized controlled trials (RCT), evaluating RDW on admission in COVID-19 patients were looked for inclusion.

The primary outcome was mortality and disease severity was the secondary outcome. Articles other than those in the English language, without full retrievable text or appropriate control group were excluded (PRISMA flow diagram). 21,22

SS, SK and PK screened all the available abstracts independently after removing the duplications to exclude the irrelevant articles.

Then, the full-texts of the eligible studies were screened to check the inclusion criteria. Any disagreements were resolved in consultation with a fourth researcher (AKS). For dichotomous data, the number of incidents and the total number of patients in each group were noted and for continuous data, means and SD are extracted. Studies with missing data have been reported descriptively.

Due to lack of consensus regarding defining the severity of the disease among studies, any patient either requiring mechanical ventilation or with a ratio of the partial pressure of arterial blood oxygen (PaO 2 )/oxygen concentration (FiO 2 ) ≤300 mm Hg is considered as severe/critically ill, and the rest of the patient's are defined as mild/moderate ill patients. 

The quality of evidence was judged independently by PK and SS with the Grading of Recommendations Assessment, Development and Evaluation (GRADE) tool, which has five downgrading factors (study limitations, indirectness, imprecision, consistency of effect and publication bias) and three upgrading factors (dose-response relation, large magnitude of the effect and plausible confounders or biases). 24, 25 The quality of evidence of every outcome is assorted as 'High', 'Moderate', 'Low' or 'Very low'. [26] [27] [28] [29] [30] [31] Any difference of opinion was resolved after consulting with AKS.

We (PK and SS) used Review Manager version 5 to conduct this frequentist meta-analysis. The odds ratio (OR) for dichotomous data and mean differences (MDs) for continuous data along with the 95% confidence intervals (CIs), respectively, were assessed as per the Cochrane Handbook for Systematic Reviews of Interventions. 32 The I 2 statistic was used for evaluating the statistical heterogeneity, a value of >50% was accepted as significant heterogeneity. A funnel plot was used to assess publication bias.

25 studies 33-57 out of 1,008 identified publications were incorporated according to the inclusion criteria ( Figure 1 ; Table 1 ). 19 articles were peer-reviewed and 6 were preprints. [35] [36] [37] 40, 45, 53 While nine articles evaluated RDW on admission to assess the severity of COVID-19 patients, others addressed RDW on admission between survivors and non-survivors. Among the included studies, nine studies had a moderate degree of bias ( Figure 2 ). (Figure 3b ).

Nine studies with a total of 3,446 patients were assessed for the severity of COVID-19. Critically ill patients are associated with increased RDW on admission (SMD = 0.46; 95%CI 0.26-0.67; Figure 4 ). Significant heterogeneity is found among studies assessing mortality and severity

We found a low quality of evidence on the impact of raised RDW on COVID-19 mortality and severity (Table 2 ).

The publication bias was assessed for the studies on COVID-19 mortality. As per the Funnel plot qualitatively a publication bias is implausible ( Figure 5 ). In the subgroup analysis, we found COVID-19 patients with initial RDW >14.5 are associated with almost double the risk of mortality.

Another recent observational multicentric study with 193 hospitalized COVID-19 patients, also found that RDW ≥14.5% were also significantly associated with increased risk of mortality 

Our study is one of the extensive & comprehensive systematic review of the effectiveness of RDW on admission in patients with COVID-19

for predicting the mortality and severity, and may be considered at this moment as the pre-eminent evidence for decision-making. The

Majority of the included studies are retrospective in nature, and six studies are not peer-reviewed. Although in the current scenario, the prognostic role of RDW in COVID-19 is promising, our findings are heterogeneous, medium in effect and of low-quality evidence. We also acknowledged that the cut-off value of RDW and the point of evaluation is yet to be standardized and information in this regard is still evolving. 

Weekly Epidemiological Update -22

Coronavirus disease 2019 case surveillance -United States

Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72,314 cases from the Chinese center for disease control and prevention

Coronavirus disease 2019 (COVID-19): a literature review

Clinical, laboratory and imaging features of COVID-19: a systematic review and meta-analysis

Early anti-SARS-CoV-2 convalescent plasma in patients admitted for COVID-19: a randomized phase II clinical trial. medRxiv

Red blood cell distribution width: a simple parameter with multiple clinical applications

Red cell distribution width and mortality in hemodialysis patients

Red cell distribution width and preeclampsia: a systematic review and meta-analysis. Clin Hypertens

Prognostic value of RDW in cancers: a systematic review and meta-analysis

High red blood cell distribution width is closely associated with risk of carotid artery atherosclerosis in patients with hypertension

Red cell distribution width is associated with incident myocardial infarction in a general population: the Tromsø Study

Systemic inflammation predicts all-cause mortality: a Glasgow inflammation outcome study

Red cell distribution width in relation to incidence of coronary events and case fatality rates: a population-based cohort study

Gender and ethnic differences in red cell distribution width and its association with mortality among low risk healthy United state adults

Red cell distribution width and common disease onsets in 240,477 healthy volunteers followed for up to 9 years

The trinity of COVID-19: immunity, inflammation and intervention

Immune response, inflammation, and the clinical spectrum of COVID-19. Front Immunol

The role of interleukin-6 in monitoring severe case of coronavirus disease 2019

Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China

The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration

Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement

ROBINS-I: a tool for assessing risk of bias in non-randomized studies of interventions

GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables

The skills and experience of GRADE methodologists can be assessed with a simple tool

GRADE guidelines: 4. Rating the quality of evidence-study limitations (risk of bias)

GRADE guidelines: 5. Rating the quality of evidence-publication bias

GRADE guidelines 6. Rating the quality of evidence-imprecision

GRADE guidelines: 7. Rating the quality of evidence-inconsistency

GRADE guidelines: 8. Rating the quality of evidence-indirectness

GRADE guidelines: 9. Rating up the quality of evidence

Updated guidance for trusted systematic reviews: a new edition of the Cochrane Handbook for Systematic Reviews of Interventions

Clinical course and outcomes of 344 intensive care patients with COVID-19

Association of red blood cell distribution width with mortality risk in hospitalized adults with SARS-CoV-2 infection

Development and validation of a survival calculator for hospitalized patients with COVID-19. medRxiv

Can routine laboratory variables predict survival in COVID-19? An artificial neural network-based approach

Estimating risk of mechanical ventilation and mortality among adult COVID-19 patients admitted to mass general Brigham: the VICE and DICE scores. medRxiv

The neutrophil-to-monocyte ratio and lymphocyte-to-neutrophil ratio at admission predict in-hospital mortality in Mexican patients with severe SARS-CoV-2 infection

The neutrophil to lymphocyte ratio and in-hospital all-cause mortality in patients with COVID-19

Dynamic Prognosis Model for Predicting Survival in Severe and Critically Ill COVID-19 Patients Using Machine Learning, 2020, PREPRINT (Version 1) available at Research Square

Association between red blood cell distribution width and mortality of COVID-19 patients

Red cell distribution width (RDW): a prognostic indicator of severe COVID-19

Red blood cell distribution width (RDW) predicts COVID-19 severity: a prospective, observational study from the cincinnati SARS-CoV-2 emergency department cohort

A tool for early prediction of severe coronavirus disease 2019 (COVID-19): a multicenter study using the risk nomogram in Wuhan and Guangdong, China

Predicting severe COVID-19 at presentation, introducing the COVID severity score (6/8/ 2020). 2020. Available at SSRN

Preliminary study to identify severe from moderate cases of COVID-19 using combined hematology parameters

Prognosis of COVID-19: red cell distribution width, platelet distribution width, and C-reactive protein

Red cell distribution width upon hospital admission predicts short-term mortality in hospitalized patients with COVID-19: a single-center experience

Laboratory test alterations in patients with COVID-19 and non COVID-19 interstitial pneumonia: a preliminary report

The relationship between serum erythropoietin, hepcidin, and haptoglobin levels with disease severity and other biochemical values in patients with COVID-19

Predictors of mortality in patients with COVID-19 infectionassociated acute kidney injury

Significance of RDW in predicting mortality in COVID-19-An analysis of 622 cases

Red blood cell distribution width (RDW) in Hospitalized COVID-19 Patients. medRxiv

Low albumin levels are associated with poorer outcomes in a case series of COVID-19 patients in Spain: a retrospective cohort study. Microorganisms

Associations between hematological parameters and disease severity in patients with SARS-CoV-2 infection

Risk factors affecting ICU admission in COVID-19 patients; Could air temperature be an effective factor?

Do initial hematologic indices predict the severity of COVID-19 patients?

Red cell distribution width as a prognostic marker in patients with community-acquired pneumonia

Red blood cell distribution is a significant predictor of severe illness in coronavirus disease

Red blood cell distribution width, disease severity, and mortality in hospitalized patients with SARS-CoV-2 infection: a systematic review and meta-analysis

Association between red blood cell distribution width and mortality and severity among patients SARKAR ET AL

COVID-19: a systematic review and meta-analysis

Increased red cell distribution width is associated with disease severity in hospitalized adults with SARS-CoV-2 infection: an observational multicentric study

Red blood cell distribution width is associated with mortality risk in patients with acute respiratory distress syndrome based on the Berlin definition: a propensity score matched cohort study

A predictive model for acute respiratory distress syndrome mortality using red cell distribution width

Evidence of structural protein damage and membrane lipid remodeling in red blood cells from COVID-19 patients

Histiocytic hyperplasia with hemophagocytosis and acute alveolar damage in COVID-19 infection

A relative ADAMTS13 deficiency supports the presence of a secondary microangiopathy in COVID 19

Can routine laboratory tests discriminate SARS-CoV-2-infected pneumonia from other causes of communityacquired pneumonia?

Role of red blood cell distribution width, as a prognostic indicator in COVID-19: A systematic review and meta-analysis